Indeed, we find that activated PI3Kδ plays a critical role in suppressing TCF1, in vitro and in vivo, as well as in in-vitro-activated CD8+ T cells from patients with APDS. The gene discussed is CD8A; the disease is activated PI3K-delta syndrome.